Prospects for Enhancing Efficacy of Radioimmunotherapy

Radioimmunotherapy has been in use for more than 20 years and has progressed significantly since its efficacy has first been demonstrated in hematology. Yet it still has limitations that prevent its large-scale clinical use. This chapter reviews recent developments to overcome these limitations including new antibody specificities, pretargeting methods, fractionated injections, and the use of alpha emitters. Immuno-PET is also likely to assist in selecting patients for radioimmunotherapy, optimizing injected activities, and noninvasively monitoring therapy efficacy.